BR0207102A - Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença - Google Patents

Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença

Info

Publication number
BR0207102A
BR0207102A BR0207102-9A BR0207102A BR0207102A BR 0207102 A BR0207102 A BR 0207102A BR 0207102 A BR0207102 A BR 0207102A BR 0207102 A BR0207102 A BR 0207102A
Authority
BR
Brazil
Prior art keywords
crystalline form
treatment
pharmaceutical composition
disease
prevention
Prior art date
Application number
BR0207102-9A
Other languages
English (en)
Inventor
Takashi Takita
Keiichi Ohtsuka
Eiji Numagami
Susumu Harashima
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BR0207102A publication Critical patent/BR0207102A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"FORMA CRISTALINA, COMPOSIçãO FARMACêUTICA, USO DE UMA FORMA CRISTALINA,, E, MéTODO PARA A PREVENçãO OU O TRATAMENTO DE DOENçA". Cristais de um derivado de nucleosídeo de pirimidina possuindo excelente atividade antitumor. São cristais de composto representado pela fórmula (I).
BR0207102-9A 2001-02-09 2002-02-06 Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença BR0207102A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001033128 2001-02-09
PCT/JP2002/000986 WO2002064609A1 (fr) 2001-02-09 2002-02-06 Cristaux de derive de nucleoside de pyrimidine

Publications (1)

Publication Number Publication Date
BR0207102A true BR0207102A (pt) 2004-01-27

Family

ID=18896929

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0207102A BRPI0207102A8 (pt) 2001-02-09 2002-02-06 forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.
BR0207102-9A BR0207102A (pt) 2001-02-09 2002-02-06 Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0207102A BRPI0207102A8 (pt) 2001-02-09 2002-02-06 forma cristalina, composição farmacêutica, e, uso de uma forma cristalina.

Country Status (21)

Country Link
EP (1) EP1364959B1 (pt)
JP (2) JP3748536B2 (pt)
KR (1) KR100679904B1 (pt)
CN (1) CN100408591C (pt)
AT (1) ATE361929T1 (pt)
AU (1) AU2002230164B2 (pt)
BR (2) BRPI0207102A8 (pt)
CA (1) CA2437994C (pt)
CY (1) CY1106685T1 (pt)
CZ (1) CZ303241B6 (pt)
DE (1) DE60220024T2 (pt)
DK (1) DK1364959T3 (pt)
ES (1) ES2286237T3 (pt)
HU (1) HU229294B1 (pt)
IL (2) IL157216A0 (pt)
MX (1) MXPA03007123A (pt)
NZ (1) NZ527393A (pt)
PT (1) PT1364959E (pt)
RU (1) RU2256666C2 (pt)
WO (1) WO2002064609A1 (pt)
ZA (1) ZA200306121B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101084525B1 (ko) 1999-09-02 2011-11-18 이비덴 가부시키가이샤 프린트배선판 및 그 제조방법
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
CA2725295C (en) 2008-06-09 2016-11-08 Cyclacel Limited Combination of sapacitabine (cndac) and dna methyltransferase inhibitors such as decitabine and procaine
WO2012140436A1 (en) 2011-04-14 2012-10-18 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
BR112017019409A2 (pt) * 2015-03-09 2018-04-24 Grace W R & Co forma cristalina de ribosídeo de nicotinamida
CA3086535A1 (en) 2017-12-22 2019-06-27 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079413C (en) * 1991-09-30 2003-09-09 Masakatsu Kaneko Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use

Also Published As

Publication number Publication date
EP1364959B1 (en) 2007-05-09
KR20030081424A (ko) 2003-10-17
EP1364959A1 (en) 2003-11-26
CY1106685T1 (el) 2012-05-23
IL157216A0 (en) 2004-02-19
EP1364959A4 (en) 2004-03-24
KR100679904B1 (ko) 2007-02-07
HUP0303159A2 (hu) 2003-12-29
CN100408591C (zh) 2008-08-06
CZ20032111A3 (cs) 2003-12-17
DE60220024D1 (en) 2007-06-21
ES2286237T3 (es) 2007-12-01
HU229294B1 (en) 2013-10-28
DE60220024T2 (de) 2007-11-22
AU2002230164B2 (en) 2005-04-07
CA2437994A1 (en) 2002-08-22
WO2002064609A1 (fr) 2002-08-22
CA2437994C (en) 2011-05-17
PT1364959E (pt) 2007-07-23
BRPI0207102A8 (pt) 2018-02-27
DK1364959T3 (da) 2007-06-04
RU2003124648A (ru) 2005-02-27
CZ303241B6 (cs) 2012-06-13
JP4356998B2 (ja) 2009-11-04
JP2002308895A (ja) 2002-10-23
CN1501939A (zh) 2004-06-02
JP3748536B2 (ja) 2006-02-22
MXPA03007123A (es) 2003-11-18
JP2006008699A (ja) 2006-01-12
IL157216A (en) 2008-03-20
ZA200306121B (en) 2005-01-26
NZ527393A (en) 2004-07-30
RU2256666C2 (ru) 2005-07-20
ATE361929T1 (de) 2007-06-15
HUP0303159A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
BR0307351A (pt) Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
NO20035524D0 (no) 4'-substituerte nukleosider
BR0109703A (pt) Derivados de piperazina
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
DK1706403T3 (da) Imidazo[4,5-c]pyridinforbindelser og fremgangsmåder til antiviral behandling
GB0206860D0 (en) Compounds
MXPA04012965A (es) Inhibidores virales.
WO2003037860A3 (en) Purine analogs having hsp90-inhibiting activity
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
BR0316771A (pt) Compostos para o tratamento ou a prevenção de infecções por flavivirus, uso de um composto e composição farmacêutica
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
NO20040881L (no) Orale antidiabetes midler.
AU2003250471A8 (en) Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
BR0113590A (pt) 7-oxo-piridopirimidinas
ATE238981T1 (de) Antitumorwirkstoffe
BR0207102A (pt) Forma cristalina, composição farmacêutica, uso de uma forma cristalina, e, método para a prevenção ou o tratamento de doença
DK1448562T3 (da) Substituerede tetracycliske pyrroloquinolonderivater egnede som phosphodiesteraseinhibitorer
SE9804212D0 (sv) Compounds
MXPA04006041A (es) Antivirales de piridoquinoxalina.
SG145570A1 (en) 4-æ7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
MXPA04004621A (es) Nucleotidos, preparaciones de los mismos y su utilizacion como inhibidores de polimerasas virales de arn.
ATE266029T1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
WO2003051838A3 (en) Protein kinase inhibitors
WO2004044174A3 (en) Topoisomerase-targeting agents

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL